NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Peterson K, McDonagh M, Thakurta S, et al. Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010 Nov.

Cover of Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs)

Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet].

Show details

References

1.
Liberati A, Altman D, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine. 2009;151(4):W65–W94. [PubMed: 19622512]
2.
Gotzsche P. Methodology and overt hidden bias in reports of 196 double-blind trials of non-steroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clinical Trials. 1989;10:31–56. [PubMed: 2702836]
3.
van Tulder MW, Scholten R, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low-back pain. Cochrane Database of Systematic Reviews. 2006;(1) [PubMed: 17636636]
4.
Traversa G, Walker AM, Ippolito FM, et al. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology. 1995 Jan;6(1):49–54. [PubMed: 7888445]
5.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289–300. [PubMed: 8037411]
6.
Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. American Journal of Medicine. 1998 Jul 27;105(1B):31S–38S. [PubMed: 9715832]
7.
Moore R, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. Journal of Medical Economics. 1999;2:45–55.
8.
Blower A, Brooks A, Fenn G, Hill A, Pearce M, Morant S. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharm Ther. 1997(11):283–291. [PubMed: 9146764]
9.
Bandolier. Cox-2 roundup. 2005. [Accessed 16 Dec 2005]. http://www​.medicine.ox​.ac.uk/bandolier/band75/b75-2.html
10.
Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?[erratum appears in Ann Intern Med 2000 Jun 20;132(12):1011] Annals of Internal Medicine. 2000 Jan 18;132(2):134–143. [PubMed: 10644275]
11.
Jenkins J, Seligman P. Memorandum: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. FDA. Apr 6, 2005. NDA files 20-998, 21-156, 21-341, 21-042.
12.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. American Journal of Preventive Medicine. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]
13.
Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews, CRD Report Number 4. 2nd. York, UK: NHS Centre for Reviews and Dissemination; 2001.
14.
Owens DK, Lohr KN, Atkins D. Grading the strength of a body of evidence when comparing medical interventions. Methods Guide for Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality; Rockville, MD: 2009. [PubMed: 19595577]
15.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2010;63(5):513–523. [PubMed: 19595577]
16.
Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. John Wiley & Sons, Inc; 2000.
17.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. [PubMed: 9250266]
18.
Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ. 2001;322(7300):1479–1480. [PMC free article: PMC1120528] [PubMed: 11408310]
19.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. [PMC free article: PMC192859] [PubMed: 12958120]
20.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. [PubMed: 12111919]
21.
Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20):2693–2708. [PubMed: 10521860]
22.
Bensen W, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clinic proceedings. 1999 Nov;74(11):1095–1105. [PubMed: 10560596]
23.
Emery P, Koncz T, Pan S, Lowry S. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clinical Therapeutics. 2008 Jan;30(1):70–83. [PubMed: 18343244]
24.
Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. The American journal of gastroenterology. 2001 Apr;96(4):1019–1027. [PubMed: 11316141]
25.
Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. Journal of International Medical Research. 2001 Nov-Dec;29(6):467–479. [PubMed: 11803730]
26.
McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scandinavian Journal of Rheumatology. 2001;30(1):11–18. [PubMed: 11252686]
27.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247–1255. [PubMed: 10979111]
28.
Singh G, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. The American Journal of Medicine. 2006. pp. 255–266. 3/06- Public Comment. [PubMed: 16490472]
29.
Zhao SZ, Fiechtner JI, Tindall EA, et al. Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care & Research. 2000 Apr;13(2):112–121. [PubMed: 14635284]
30.
Zhao S, McMillen J, Markenson J, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy. 1999;19(11):1269–1278. [PubMed: 10555933]
31.
Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: Comparative Effectiveness Review. Agency for Healthcare Research and Quality; 2006.
32.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002 Sep 21;325(7365):619. [PMC free article: PMC126301] [PubMed: 12242171]
33.
Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Research & Therapy. 2005;7(3):R644–665. [PMC free article: PMC1174947] [PubMed: 15899051]
34.
Bertin P, Behier JM, Noel E, Leroux JL. Celecoxib is as efficacious as naproxen in the management of acute shoulder pain. Journal of International Medical Research. 2003 Mar-Apr;31(2):102–112. [PubMed: 12760313]
35.
Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. American Journal of Orthopedics (Chatham, Nj) 2002;31(8):445–451. [PubMed: 12216965]
36.
Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis & Rheumatism. 2001 Jan;44(1):180–185. [PubMed: 11212158]
37.
Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. Journal of Rheumatology. 2006 Sep;33(9):1805–1812. [PubMed: 16960941]
38.
Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Annals of the Rheumatic Diseases. 2008 Mar;67(3):323–329. [PubMed: 17616556]
39.
Emery P, Kong S X, Ehrich E W, Watson D J, Towheed T E. Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review (Structured abstract) Clinical Therapeutics. 2002;24(8):1225–1291. [PubMed: 12240779]
40.
Simon L, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA : the journal of the American Medical Association. 1999 Nov;282(20):1921–1928. [PubMed: 10580457]
41.
Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. British Journal of Rheumatology. 1998 Sep;37(9):946–951. [PubMed: 9783758]
42.
Furst D, Hall DB, Roszko J, Leonard JP. Efficacy, safety and dose response of meloxicam up to 22.5 mg in the treatment of rheumatoid arthritis (RA): results of a phase III double-blind, placebo controlled trial. Zeitschrift fur Rheumatologie. 2001;60(Suppl 1):38.
43.
Goei The HS. Lund B, Distel MR, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis & Cartilage. 1997 Jul;5(4):283–288. [PubMed: 9404473]
44.
Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.[erratum appears in Br J Rheumatol 1998 Oct;37(10):1142] British Journal of Rheumatology. 1998 Sep;37(9):937–945. [PubMed: 9783757]
45.
Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. British Journal of Rheumatology. 1996 Apr;35(Suppl 1):39–43. [PubMed: 8630635]
46.
Hosie J, Distel M, Bluhmki E. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee. A six-month double-blind study. Clinical Drug Investigation. 1997;13(4):175–184.
47.
Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. British Journal of Rheumatology. 1996 Apr;35(Suppl 1):35–38. [PubMed: 8630634]
48.
Valat JP, Accardo S, Reginster JY, et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflammation Research. 2001 Mar;50(Suppl 1):S30–34. [PubMed: 11339519]
49.
Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. British Journal of Rheumatology. 1996 Apr;35(Suppl 1):22–28. [PubMed: 8630632]
50.
Jenner P. Nabumetone in the treatment of skin and soft tissue injury. American Journal of Medicine. 1987;83(suppl 4B):101–106. [PubMed: 3318420]
51.
Watson M, Brookes ST, Faulkner A, Kirwan J. Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2006;(1) [PubMed: 17636601]
52.
Rogind H, Bliddal H, Klokker D, Jensen F. Comparison of etodolac and piroxicam in patients with osteoarthritis of the hip or knee: A prospective, randomised, double-blind, controlled multicentre study. Clinical Drug Investigation. 1997;13(2):66–75. [PubMed: 18370453]
53.
Liang TH, Hsu PN. Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. Current Medical Research & Opinion. 2003;19(4):336–341. [PubMed: 12841927]
54.
Towheed TE, Hochberg MC, Shea BJ, Wells G. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database of Systematic Reviews. 2006;(1) [PubMed: 17636642]
55.
Roelofs, Pepijn DDM, Deyo, et al. Non-steroidal anti-inflammatory drugs for low back pain [Systematic Review] Cochrane Database of Systematic Reviews. 2007;2010:3.
56.
Herrera JA, Ramos R, Fuentes P, Gonzalez M. Evaluation of the effectiveness and tolerability of controlled-release diclofenac-potassium versus immediate-release diclofenac-potassium in the treatment of knee osteoarthritis. Current Therapeutic Research - Clinical and Experimental. 2007;68(2):82–93.
57.
Prabhu VV. A comparative clinical trial evaluating efficacy and safety of fixed dose combination of nimesulide (100 mg) and racemethionine (50 mg) (namsafe) versus reference drug (nimesulide) and other NSAIDs in the treatment of osteoarthritis. Journal of the Indian Medical Association. 2008 Jun;106(6):402–404. [PubMed: 18839654]
58.
Wagenitz A, Mueller EA, Frentzel A, Cambon N. Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac's use in this patient population. Current Medical Research & Opinion. 2007 Aug;23(8):1957–1966. [PubMed: 17631698]
59.
Deodhar SD, McLeod MM, Dick WC, Buchanan WW. A short-term comparative trial of salsalate and indomethacin in rheumatoid arthritis. Current Medical Research & Opinion. 1977;5(2):185–188. [PubMed: 340137]
60.
Bombardier C, Peloso PM, Goldsmith CH., Group S-DS. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Journal of Rheumatology. 1995 Apr;22(4):617–624. [PubMed: 7791151]
61.
Riedemann PJ, Bersinic S, Cuddy LJ, Torrance GW, Tugwell PX. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. Journal of Rheumatology. 1993 Dec;20(12):2095–2103. [PubMed: 8014938]
62.
Sorkin EM, Brogden RN. Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain states. Drugs. 1985 Mar;29(3):208–235. [PubMed: 3886353]
63.
Scott DL, Berry H, Capell H, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology. 2000 Oct;39(10):1095–1101. [PubMed: 11035129]
64.
Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886] BMC Musculoskeletal Disorders. 2005;6:44. [PMC free article: PMC1201146] [PubMed: 16086839]
65.
Bookman AAM, Williams KSA, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2004 Aug;171(4):333–338. [PMC free article: PMC509045] [PubMed: 15313991]
66.
Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Archives of Internal Medicine. 2004 Oct 11;164(18):2017–2023. [PubMed: 15477437]
67.
Altman RD, Dreiser R-L, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology. 2009 Sep;36(9):1991–1999. [PubMed: 19648310]
68.
Barthel HR, Haselwood D, Longley 3 S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Seminars in Arthritis & Rheumatism. 2009 Dec;39(3):203–212. [PubMed: 19932833]
69.
Bruhlmann P, Michel BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clinical & Experimental Rheumatology. 2003 Mar-Apr;21(2):193–198. [PubMed: 12747273]
70.
Roth S, Willoughby DA, Maddin S, Vanzieleghem M, Fraser R. A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. Round Table Series Royal Society of Medicine. 1995;40:132–137. [PubMed: 8867642]
71.
Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. Journal of Rheumatology. 2005 Dec;32(12):2384–2392. [PubMed: 16331769]
72.
Dreiser RL, Tisne-Camus M. DHEP plasters as a topical treatment of knee osteoarthritis--a double-blind placebo-controlled study. Drugs under experimental and clinical research. 1993;19(3):117–123. [PubMed: 8112200]
73.
Galeazzi M, Marcolongo R. A placebo-controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases. Drugs under experimental and clinical research. 1993;19(3):107–115. [PubMed: 8112199]
74.
Simon LS, Grierson LM, Naseer Z, Bookman AAM, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009 Jun;143(3):238–245. [PubMed: 19380203]
75.
Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. Journal of Rheumatology. 2004 Oct;31(10):2002–2012. [PubMed: 15468367]
76.
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. New England Journal of Medicine. 2006 Aug 31;355(9):873–884. [PubMed: 16943400]
77.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine. Nov 23, 2000. pp. 1520–1528. p following 1528, 2000. [PubMed: 11087881]
78.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine. 2005;352:1092–1102. [PubMed: 15713943]
79.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson J R, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis: meta-analysis of randomised trials (Structured abstract) BMJ. 2006;332:1302. [PMC free article: PMC1473048] [PubMed: 16740558]
80.
Mukherjee D, Nissen S, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959. [PubMed: 11509060]
81.
White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. American Journal of Cardiology. 2002;89:425–430. [PubMed: 11835924]
82.
Garner SE, Fidan DD, Frankish RR, et al. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2006;(1)
83.
Goldstein JL. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. Journal of Rheumatology - Supplement. 2000 Oct;60:25–28. [PubMed: 11032099]
84.
Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287–1288. [PMC free article: PMC1123260] [PubMed: 12039807]
85.
Rostom A, Dube C, Jolicoeur E, Boucher M, Joyce J. Gastroduodenal ulcers associated with the use of non-steriodal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Canadian Coordinating Office for Heatlh Technology Assessment, Technology Overview no 12. 2004
86.
Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis & Rheumatism. 2005;52(7):1968–1978. [PubMed: 15986365]
87.
USFDA. Advisory Committee Briefing Document: Celecoxib and Valdecoxib Cardiovascular Safety. 2005. [Accessed 21 Dec 2005]. http://www​.fda.gov/ohrms​/dockets/ac/05/briefing​/2005-4090B1_03​_Pfizer-Celebrex-Bextra.pdf
88.
Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.[erratum appears in Am J Ther 2000 Sep;7(5):341] American Journal of Therapeutics. 2000 May;7(3):159–175. [PubMed: 11317165]
89.
White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. American Journal of Therapeutics. 2004 Jul-Aug;11(4):244–250. [PubMed: 15266215]
90.
Witter J. Celebrex Capsules (Celecoxib) NDA 20-998/S-009 Medical Officer Review. [Accessed 21 Dec, 2005]. http://www​.fda.gov/ohrms​/dockets/ac/01/briefing​/3677b1_03_med.pdf
91.
Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. Meta-analysis of randomized trials. JAMA. 2006;296 [PubMed: 16968832] [Cross Ref]
92.
Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygnease 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475–481. [PubMed: 15705456]
93.
Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366. [PMC free article: PMC558288] [PubMed: 15947398]
94.
Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Archives of Internal Medicine. 2005 May 9;165(9):978–984. [PubMed: 15883235]
95.
Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157–164. [PubMed: 15684203]
96.
Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.[summary for patients in Ann Intern Med. 2005 Apr 5;142(7):I45; PMID: 15809454] Annals of Internal Medicine. 2005 Apr 5;142(7):481–489. [PubMed: 15809459]
97.
Mamdani M, Rochon PA, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481–486. [PubMed: 12588209]
98.
Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624. [PMC free article: PMC126302] [PubMed: 12242172]
99.
McGettigan P, Henry D. Cardiovascular risk and inhibiton of cycloxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;2006 [PubMed: 16968831] [Cross Ref]
100.
Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002 Jan 12;359(9301):118–123. [PubMed: 11809254]
101.
Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective cyclooxygenase-2 inhibition and cardiovascular effects. Arch Intern Med. 2005;165:181–186. [PubMed: 15668364]
102.
Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068–2073. [PubMed: 15096449]
103.
Hippisley-Cox J, Coupland C, L R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331(7528):1310–1316. [PMC free article: PMC1298853] [PubMed: 16322018]
104.
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut. May 10, 2006. epublication. [PMC free article: PMC1856452] [PubMed: 16687434]
105.
Chan F, Hung, LC, Suen, BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.[comment] New England Journal of Medicine. 2002;347(26):2104–2110. [PubMed: 12501222]
106.
Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clinical Gastroenterology & Hepatology. 2007 Oct;5(10):1167–1174. [PubMed: 17916545]
107.
Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. American Journal of Medicine. 2005;118:1271–1278. [PubMed: 16271912]
108.
Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007 May 12;369(9573):1621–1626. [PubMed: 17499604]
109.
Rahme E, Barkun AN, Toubouti Y, et al. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis & Rheumatism. 2007 Jun 15;57(5):748–755. [PubMed: 17530673]
110.
Chan F, Lanas A, Scheiman J, Berger M, Nguyen H, Goldstein J. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–179. [PubMed: 20638563]
111.
Chen LC, Ashcroft D M. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials (Structured abstract) Pharmacoepidemiology and Drug Safety. 2007;16(7):762–772. [PubMed: 17457957]
112.
USFDA. Advisory Committee Briefing Document: Celecoxib and Valdecoxib Cardiovascular Safety. 2005. [Accessed 13 Aug 2010]. http://www​.fda.gov/ohrms​/dockets/ac/05/briefing/2005-4090b1​.htm
113.
Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Journal of the Royal Society of Medicine. 2006;99:132–140. [PMC free article: PMC1383759] [PubMed: 16508052]
114.
Chen LC, Ashcroft D M. Do selective COX-2 inhibitors increase the risk of cerebrovascular events: a meta-analysis of randomized controlled trials (Structured abstract) Journal of Clinical Pharmacy and Therapeutics. 2006;31(6):565–576. [PubMed: 17176361]
115.
White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. American Journal of Cardiology. 2003 Aug 15;92(4):411–418. [PubMed: 12914871]
116.
White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. American Journal of Cardiology. 2007 Jan 1;99(1):91–98. [PubMed: 17196469]
117.
Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Journal of the Medical Association of Thailand. 2009 Dec;92(Suppl 6):S19–26. [PubMed: 20128070]
118.
Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology & Drug Safety. 2006 Sep;15(9):641–652. [PubMed: 16392153]
119.
Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney International. 2006 Oct;70(8):1495–1502. [PubMed: 16941030]
120.
Aw T-J, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Archives of Internal Medicine. 2005 Mar 14;165(5):490–496. [PubMed: 15710786]
121.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcified Tissue International. 2006 Aug;79(2):84–94. [PubMed: 16927048]
122.
Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Annals of the Rheumatic Diseases. 2004;63(7):759–766. [PMC free article: PMC1755051] [PubMed: 15194568]
123.
Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clinical Gastroenterology & Hepatology. 2005 May;3(5):489–498. [PubMed: 15880319]
124.
Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. American Journal of Medicine. 1999 Dec 13;107(6A):48S–54S. [PubMed: 10628593]
125.
Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. American Journal of Medicine. 2004 Jul 15;117(2):100–106. [PubMed: 15234645]
126.
Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clinical Therapeutics. 2000;22(4):400–410. [PubMed: 10823362]
127.
Mann J, Evans T. Gastrointestinal-related complications in a long-term care population taking NSAIDs versus COX-2 inhibitor therapy. Consultant Pharmacist. 2004;19(7):602–612. [PubMed: 16553490]
128.
Jick SS. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy. 2000;20(7):741–744. [PubMed: 10907963]
129.
Huang JQ, Sridhar S, Hunt R H. Gastrointestinal safety profile of nabumetone: a meta-analysis (Structured abstract) Database of Abstracts of Reviews of Effects. 1999;107(6A):55s–64s. [PubMed: 10628594]
130.
Ashworth NL, Peloso PM, Muhajarine N, Stang M. A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. Journal of Rheumatology. 2004 May;31(5):951–956. [PubMed: 15124256]
131.
Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–571. [PMC free article: PMC2014603] [PubMed: 11736865]
132.
Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology. 2004;127(5):1322–1328. [PubMed: 15521001]
133.
Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22;312(7046):1563–1566. [PMC free article: PMC2351326] [PubMed: 8664664]
134.
Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologi studies published in the 1990s. Arch Intern Med. 2000;160:2093–2099. [PubMed: 10904451]
135.
Laporte J-R, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety. 2004;27(6):411–420. [PubMed: 15144234]
136.
Silverstein F, Graham D, Senior J, et al. Misoprostol reduces gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–249. [PubMed: 7611589]
137.
Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948. [PMC free article: PMC524106] [PubMed: 15475342]
138.
Rostom, Alaa, Dube, et al. Prevention of NSAID-induced gastroduodenal ulcers [Systematic Review] Cochrane Database of Systematic Reviews. 2009;1:1.
139.
Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 Dec 4-10;364(9450):2021–2029. [PubMed: 15582059]
140.
Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology. 2004;43(6):985–990. [PubMed: 15028354]
141.
Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction.[erratum appears in Arch Intern Med 2002 Sep 9;162(16):1858] Archives of Internal Medicine. 2002 May 27;162(10):1111–1115. [PubMed: 12020180]
142.
Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099–1104. [PubMed: 12020178]
143.
Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolis cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105–1110. [PubMed: 12020179]
144.
Graham DJ. Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs. 2006. [Accessed 5 Jan 2006]. http://www​.fda.gov/ohrms​/dockets/ac/05/slides​/2005-4090S2_02_FDA-Graham_files​/frame.htm
145.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–484. [PubMed: 8435027]
146.
Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. American Journal of Gastroenterology. 2009 Feb;104(2):356–362. [PubMed: 19174782]
147.
Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharm Ther. 2004;20:373–380. [PubMed: 15298630]
148.
Fries JF, Williams C, Bloch D. The Relative Toxicity of Nonsteroidal Antiinflammatory Drugs. Arthritis & Rheumatism. 1991. pp. 1353–1360. 1/6/06. [PubMed: 1953813]
149.
Fries JF, Ramey DR, Singh G, Morfeld D, Bloch DA, Raynauld JP. A reevaluation of aspirin therapy in rheumatoid arthritis. Archives of Internal Medicine. 1993 Nov 8;153(21):2465–2471. [PubMed: 8215751]
150.
Fries JF. Toward an Understanding of NSAID-Related Adverse Events: The Contribution of Longitudinal Data. Scand J Rheuamtol. 1996. pp. 3–8. 1/6/06. [PubMed: 8628980]
151.
Calin A, Cawley MI, Pal B, Rosenberg JN, Silas AM, Williams PI. Multicentre double-blind comparison of sustained action formulations of tiaprofenic acid and indomethacin in osteoarthritis. Drugs. 1988;(35 Suppl 1):57–63. [PubMed: 3282867]
152.
Maccagno A, Sebastian O, Di Giorgio E. Comparative double-blind study of tiaprofenic acid versus piroxicam in the treatment of osteoarthritis of the knee. Drugs. 1988;(35 Suppl 1):64–67. [PubMed: 3282868]
153.
Buchbinder R, Forbes A, Kobben F, Boyd I, Snow RM, McNeil JJ. Clinical features of tiaprofenic acid (surgam) associated cystitis and a study of risk factors for its development. Journal of Clinical Epidemiology. 2000 Oct;53(10):1013–1019. [PubMed: 11027933]
154.
Harrison WJ, Willis RG, Neal DE. Adverse reactions to tiaprofenic acid mimicking interstitial cystitis. BMJ. 1994 Sep 3;309(6954):574. [PMC free article: PMC2541417] [PubMed: 8086944]
155.
Lindquist M, Pettersson M, Edwards IR, et al. How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. Pharmacology & Toxicology. 1997 May;80(5):211–217. [PubMed: 9181599]
156.
Lisse J, Espinoza L, Zhao SZ, Dedhiya SD, Osterhaus JT. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. The Journals of Gerontology Series A, Biological Sciences and Medical Sciences. 2001 Mar;56(3):M167–175. [PubMed: 11253158]
157.
Dahlberg LE, Holme I, Hoye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scandinavian Journal of Rheumatology. 2009 Mar-Apr;38(2):133–143. [PubMed: 19165648]
158.
Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–1756. [PubMed: 15172772]
159.
Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis & Rheumatism. 2008 Aug 15;59(8):1097–1104. [PMC free article: PMC2884183] [PubMed: 18668605]
160.
Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar;43(3):573–577. [PubMed: 14744921]
161.
Dentali F, Douketis JD, Woods K, et al. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Annals of Pharmacotherapy. 2006 Jul-Aug;40(7-8):1241–1247. [PubMed: 16804099]
162.
Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–192. [PubMed: 15668365]
163.
Knijff-Dutmer EAJ, Schut GA, van de Laar MAFJ. Concomitant coumarin-NSAID therapy and risk for bleeding. Annals of Pharmacotherapy. 2003 Jan;37(1):12–16. [PubMed: 12503926]
164.
MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–574. [PubMed: 12598144]
165.
Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–3006. [PubMed: 15197149]
166.
Norgard B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther. 2004;19:817–825. [PubMed: 15043523]
167.
Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330:1370. [PMC free article: PMC558290] [PubMed: 15947399]
Copyright © 2010, Oregon Health & Science University.
Bookshelf ID: NBK53959
PubReader format: click here to try

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...